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INTRODUCTION 
Since the invention of the first implantable shunt valve by Nulsen and 
Spitz (12) almost 50 years ago, there has been a remarkable number of 
ingenious modifications and new designs of shunt equipment to treat pe-
diatric hydrocephalus. These developments were in response to the im-
mediately evident high shunt failure rate. These designs included anti-
siphon devices (15), on-off devices, gravity-actuated changes in opening 
pressure, and even externally adjustable valves, some with electromag-
netic programmers (16) (Fig. 18.1). Aside from the introduction of the 
silicone elastomer material, there has in fact been little clinical impact 
on the treatment with patients with shunts. Moreover, there has been a 
recognition of the unexpected complications-cor pulmonale (11) and 
shunt nephritis (19) from cardiac shunts, bowel erosion from spring-
coiled catheters (1), obstruction of anti-siphon devices by capsule for-
mation (3), and tonsilar herniation by lumboperitoneal shunts (2). In 
fact, each new shunt equipment design has in many cases brought along 
its own unique set of complications. 
Interpretation of the results of new shunt hardware was often ham-
pered by the design of the studies. They often contained small retro-
spective series of patients, loosely defined inclusion criteria, poor defi-
nition of outcome events, short follow-up, and inappropriate statistical 
analysis. These studies were often conducted by enthusiasts of the de-
vices who had vested interests in the outcome, including financial in-
centives. Early enthusiastic reports were often followed by less enthu-
siastic ones, often about unexpected complications. 
PROSPECTIVE RANDOMIZED TRIALS OF CSF SHUNT VALVE DESIGN 
Pediatric Shunt Design Trial 
With the recent advances in valve design, aimed at reducing shunt 
overdrainage in the upright position, there were again reports of im-
proved outcome in slightly improved but nevertheless significantly 
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FIG. 18.1 Schematic diagrams of a number of valve designs starting with the original 
Nulsen and Spitz valve developed in the early 1950s (12). The designs reflect the progress 
valve development including antisiphon devices, gravity-actuated valves, and ultimately 
an externally adjustable valve. Unfortunately, the increased complexity and sophistica-
tion has not to date resulted in improved efficacy. 
flawed clinical series (8, 18). It was at this point that the Pediatric Hy-
drocephalus Treatment and Evaluation Group decided to launch a care-
fully controlled prospective randomized trial on the Orbis Sigma valve 
(NMT, Boston, MA) (18), a flow-limiting device, and the Delta valve 
(Medtronic PS Medical, Goletta, CA) (8), a siphon control device, com-
pared to standard differential pressure valves. The trial was well orga-
nized and multicentered, the blinded data were collected centrally, and 
the primary outcome event was clearly defined and blindly adjudicated 
(4). An adequate number of patients was recruited and followed. There 
was no difference in shunt failure rates between the three types of valve 
design at an average follow-up of 2 years (5) (Fig. 18.2). The patients 
were subsequently followed for an additional 3 years, and no obvious 
changes from the initial analysis were noted (9). 
In this trial, shunt failure occurred at an exponential rate for the first 
year and then leveled off. Overall, the one-year failure rate was 40%, 





















.2~ ______ ~ ______ ~ ________ ~ ______ -r ______ ~r-______ ~ 
o 6 12 18 24 30 36 
Month of Study 
FIG. 18.2 Results of the prospective randomized trial of valve design comparing the 
Delta valve, the Orbis Sigma valve, and "standard" valves. There is no difference in com· 
plication free shunt survival between the three groups. From Ref. 5 with permission. 
and the two-year failure rate was 50%, remarkably similar to what had 
been reported before, and upon which the trial estimates for sample 
size had been based. The commonest cause of shunt failure was ob-
struction (31.4%) followed by infection (8.1 %), overdrainage (3.5%), and 
loculated ventricles (0.6%). 
SECONDARY OUTCOMES 
A number of other extremely interesting findings emerged from the 
data collected, which, though not part of the primary outcome, never-
theless shed some light on the state of treatment of pediatric hydro-
cephalus at the time. The secondary outcome measures of type of shunt 
failure and site of shunt obstruction indicated that the Delta valve, 
which was designed to prevent subdural collections, actually had the 
highest number (5). The Orbis-Sigma valve had very few obstructions 
of the ventricular catheter (the commonest site of shunt obstruction) 
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but a higher number of valve failures, as though the site of obstruction 
had been moved downstream. 
The trial received considerable attention, as well as some criticism. 
Some claimed that the valves were never designed for small children, 
that the wrong "level" of Delta valve was used, and that the results 
would have been different in older children. In fact, these valves were 
being implanted in enormous numbers of children at the time of the 
study; the number of overdrainage complications was similar in chil-
dren over age 2; and inspection of the shunt survival curves for differ-
ent standard valve opening pressures, or different Delta valve "levels," 
indicated that it likely had little effect. Since three very different valve 
designs had no apparent effect, the trial authors felt it was unlikely 
that small differences in valve design would have had much effect. 
POST HOC ANALYSIS 
There was a great deal of data collected during the trial that could be 
examined, particularly to explore whether previously held suppositions 
were possibly correct or could more appropriately be put to a subse-
quent clinical trial. There was no apparent difference in outcome ac-
cording to whether the burr hole was frontal or occipital, whether the 
ventricular catheter was placed with assistance (ultrasound, en-
doscopy, or x-ray), the training level of the surgeon, or whether the hair 
was clipped, shaved, or left alone. 
Perhaps the most interesting follow-up information was on the 
analysis of the considerable imaging data that had been collected. Each 
patient had up to six follow-up radiologic images. Excluding the images 
taken at the time of shunt failure, each image was analyzed for the size 
of the ventricles, the position of the tip of the ventricular catheter 
within the ventricle (frontal, occipital, or body), and the catheter tip en-
vironment (surrounded by CSF, touching ventricular wall, surrounded 
by slit ventricle). Ventricular size was measured using a modified 
Evan's ratio, which was an average of the frontal and occipital horn 
width divided by the maximum biparietal diameter. This ratio had been 
shown to be an accurate and reliable estimate of ventricular volume in 
pediatric patients (10, 13). 
The ventricular size declined at an exponential rate reaching a min-
imum plateau at 1 year. Remarkably, there was no difference in ven-
tricular size among the three valves (22) (Fig. 18.3). This was extremely 
interesting because the valves behave quite differently on bench test-
ing. It had also been previously reported in a retrospective review with 
historical controls that the Orbis-Sigma valve in particular kept the 
ventricles enlarged (17). The newer valves had been designed with cer-
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FIG. 18.3 Ventricular size as a function of time post shunt implantation from image 
data from the shunt design trial. There is no difference in ventricular size among the 
three valves, which have very different pressure/flow characteristics. From Ref. 22 with 
permission. 
tain assumptions made about the brain's mechanical properties and the 
response to shunt implantation. These models are based on the limited 
knowledge of CSF production and pressure changes seen over very brief 
time periods (7). These ventricle size measurements from this study 
suggest that the current biomechanical models are woefully inadequate 
and must address much larger time scales-on the order of a year. A fol-
low-up baseline study for a newly shunted patient, to determine ven-
tricular size when the patient is well, should also be carried out at ap-
proximately 1 year after implantation. 
The position of the ventricular catheter and the amount of CSF sur-
rounding it also appeared to have an effect on shunt failure (22) (Table 
18.1). By multivariate analysis, having a catheter in the occipital horn 
had a hazard ratio of .45 compared to catheters in the body of the ven-
tricle. Ventricular catheters surrounded by CSF had a hazard ratio of 
.21 compared to those in a slit ventricle. The position and environment 
of the ventricular catheter tip accounted for fully three-quarters of the 
variability of the multivariate model, indicating that they are likely 
very significant risk factors. Maintaining a catheter tip surrounded by 
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TABLE 18.1 
Independent Predictors of Cerebrospinal Fluid Shunt Malfunction 
Hazard 
Predictors Ratio 95% Cl PValue R2 
Etiology Myelomeningocele 1.78 1.18-2.67 0.006 0.037 
Head Injury 4.56 1.07-19.39 0.04 0.018 
Ventricular 2.331 1.08-5.00 0.03 0.025 
size 
Ventricular Occipital 0.45 0.28--0.74 0.001 0.052 
catheter 
location 
Frontal 0.60 0.39-0.91 0.02 0.033 
Ventricular CSF 0.21 0.094-0.45 0.0001 0.13 
catheter 
environment Touching Brain 0.33 0.21-0.51 0.0001 0.16 
lHR of 2.33 refers to an increase in the risk of shunt malfunction for every unit increase 
in the ventricular size (as per the modified Evans' ratio). 
CSF in an expanded occipital horn might significantly reduce shunt 
failure. Whereas this might seem like common sense, this is really the 
first time this has been demonstrated using prospectively collected data 
analyzed by multivariate methods. It should be added that there are 
many "common sense" solutions to shunt failure, such as using "more 
physiologic valves," which have not proved to have treatment value. 
Other factors that might affect shunt failure were included in image 
data analysis. Etiology, namely myelomeningocele, also increased the 
risk of shunt failure. Although this is not a modifiable risk factor, iden-
tification of high risk groups is important to target those who might 
benefit the most from treatment changes. 
The Medos Programmable Valve Randomized Trial 
A subsequent prospective randomized trial comparing the Medos valve 
(Johnson & Johnson, Randalph MA), a programmable differential pres-
sure valve, to all other valves also found no difference in reoperation rate 
for shunt failure (14). The trial was somewhat different in that it included 
pediatric and adult patients undergoing a first shunt insertion or valve 
revision. Nevertheless, the 2-year shunt survival rates for the patients 
for the first shunt insertion were 52% in the Medos group and 50% in the 
control group, remarkably similar to the previous randomized valve de-
sign study. Although the valve was frequently reprogrammed (66% of the 
patients) and this was felt to avert an operation in 61 patients, the over-
all reoperation rate was the same in the control group. Only four valves 
required explantation because of an inability to reprogram. 
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REPEATED SHUNT FAILURE 
In the Medos trial referred to above, patients having a subsequent 
shunt operation including a valve revision fared slightly worse than the 
first implantation group, with 2-year survival rates of 43% in both 
groups. The issue of repeated shunt failure, particularly in the same pa-
tient, is a complex one. We enrolled a cohort of patients over 10 years 
into a hydrocephalus data base. Each patient was then followed for up 
to 10 years for any episodes of shunt failure to determine what if any 
were risk factors (21). The data were then analyzed by multivariable 
time to event analysis. 
There were 1183 shunt failures in 839 patients. Failure time from the 
first shunt procedure was an important predictor for second and third 
failures so that if an individual patient failed early, they were likely to 
fail early again-and this was not a particular effect of infection. Age of 
less than 40 weeks' gestation at time of first shunt implantation had a 
hazard ratio of 2.49 (95% CI, 1.68-3.68) for the first failure and re-
mained high for subsequent failures. Age of 40 weeks to 1 year (at the 
time of the initial surgery) also proved to be an important predictor of 
first malfunctions (HR = 1.77,95% CI = 1.29-2.44). The etiology ofhy-
drocephalus was significantly associated with the risk of initial failure 
and, to a lesser extent, later failures. Concurrent other surgical proce-
dures were associated with an increased risk of failure (Table 18.2). 
It was also interesting to note what did not appear to carry any risk 
for first or subsequent failures: valve design (standard/flow regulated), 
distal catheter design (slit/open ended), antibiotic prophylaxis, emer-
gency/ASA class, burr hole site (frontal/occipital), burr hole side (left/ 
right), duration of surgery, or preadmission stay. Although it was dis-
appointing that easily modifiable factors were not important, never-
theless it identified patients at high risk. It also suggests that there is 
a process initiated by shunt failure, perhaps an inflammatory response, 
that leads to further shunt failure. 
CONCLUSION 
What should be our treatment goals over the next decade as we en-
ter the next millennium? It seems eminently reasonable that neuro-
surgeons could achieve a I-year failure rate of 5% including an infec-
tion rate of 1 %. How can this be achieved? It seems clear that this will 
require a cooperative multifaceted approach. There is much about the 
complex interactions between the hydrocephalic patient and the shunt, 
which are not well understood. Better mathematical models would al-
low simulations of the response of the hydrocephalic patient to be car-
ried out more accurately and over a much longer time scale. These mod-
TABLE 18.2 
Hazard Ratios, 95% Confidence Interval, and P Values for the First Three Failure Groups 
Failure Groups (") t>:l 
1st 2nd 3rd ~ t>:l 
t:C 
Hazard Hazard Hazard ::>:l 
Risk Factors Ratio 95% C.L PValue Ratio 95% C.I. PValue Ratio 95% C.l. PValue 0 UJ 
'"d 
Gap time of previous failure 1.72 1.28-2.30 <0.001 1.50 1.05-2.16 0.027 
.... 
~ Age* 
Less than 40 weeks 2.49 1.68-3.68 <0.001 1.59 0.93-2.74 0.096 1.71 1.05-2.79 0.032 I"lj 
40 weeks to 1 year 1.77 1.29--2.44 <0.001 1.33 0.84-2.11 0.22 0.90 0.57-1.42 0.65 t"" cj 
Etiology** Not .... tj 
significant UJ 
::r: Aqueductal stenosis 1.83 1.13-2.96 0.01 0.77 0.36-1.64 0.50 cj 
IVH 1.78 1.18-2.68 0.006 1.85 1.03-3.33 0.039 ~ 
Postmeninigitic 2.08 1.26-3.44 0.004 2.32 1.19--4.54 0.014 >-3 
Myelomeningocele 1.95 1.34-2.85 0.001 1.10 0.63-1.92 0.74 t>:l (") 
Posttraumatic 2.80 1.39--5.64 <0.004 1.86 0.67-5.18 0.23 ::r: 
Tumor 2.33 1.48-3.68 <0.001 2.34 1.22-4.48 0.01 Z 0 
Other 1.56 1.03-2.35 0.03 1.31 0.72-2.39 0.38 t"" 0 Ventriculoperitoneal vs. 0.69 0.50-0.95 0.92 Not significant Not 0 
other shunt types significant ...:: 
Concurrent surgery 1.44 1.06-1.94 0.02 Not significant 1.89 1.01-3.53 0.047 
*Corrected for gestation; age greater than 1 year is chosen as the reference category. 
**Congenital is the reference category. 
C&:> 
*'" C&:> 
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els are not easy to develop, as there is little known about even the nor-
mal mechanical parameters of the brain. Animal models of shunt fail-
ure would also allow the mechanisms of particularly proximal catheter 
occlusion to be dissected, including possible reactive mechanisms in-
duced by repetitive trauma. Ongoing clinical trials are also extremely 
important; hypotheses such as placing a ventricular catheter in an ex-
panded occipital horn need to be tested by prospective studies, as is cur-
rently being done with endoscopic placement of ventricular catheters. 
The search for new shunt designs and new materials should continue. 
No one should conclude that shunt valve designs are not important. 
Whereas the shunt design trials have been negative to date, valves have 
important effects that just have not as yet been translated into improved 
outcome. The search for alternative treatment strategies should also 
continue, i.e., endoscopic third ventriculostomy, but should be subjected 
to the same scrutiny as the clinical trials in CSF shunts (20). 
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